Daiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker hopes new data in atrial fibrillation (AFib) could accelerate its growth.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Daiichi Sankyo has launched its Lixiana product onto the UK market, where it becomes the fourth novel oral anti-coagulant (NOAC) available to treat and prevent clot-related disorders. Lixiana ...

The apex court has been hearing a petition filed by Daiichi Sankyo alleging the non-payment of ₹35 billion. The amount had been awarded to the Japanese firm in a previous arbitration in mid-2016 ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

Our collaboration with Daiichi Sankyo is an exciting opportunity to unlock therapeutic access to new cell types, paving the way for precision treatments that can transform patient outcomes.” ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...